title: Radioimmunotherapy of brain tumor.
abstract: Despite years of intensive research, the prognosis of high-grade gliomas (HGG) remains poor, as these tumors are highly resistant to currently available therapies. Therefore, there is a need for the development of new therapeutic strategies, such as the use of monoclonal antibodies (MoAbs) in association with radioisotopes, in order to achieve better responses and prognosis. This article describes our experience in radioimmunotherapy (RIT) with MoAbs and tumor pre-targeting with the avidin-biotin system, either in systemic or locoregional administrations. This therapy offers the exciting prospect of increasing the specificity of tumor cell irradiation with radioisotopes. We suggest that RIT, both systemic and locoregional, should be used as part of a combined modality approach: in combination with surgery, radiotherapy and chemotherapy.
authors.affiliation: Division of Nuclear Medicine, European Institute of Oncology, Milano, Italy.
authors.forename: Giovanni
authors.initials: G
authors.lastname: Paganelli
authors.forename: Mirco
authors.initials: M
authors.lastname: Bartolomei
authors.forename: Chiara
authors.initials: C
authors.lastname: Grana
authors.forename: Mahila
authors.initials: M
authors.lastname: Ferrari
authors.forename: Paola
authors.initials: P
authors.lastname: Rocca
authors.forename: Marco
authors.initials: M
authors.lastname: Chinol
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000188:drug therapy / Q000532:radiotherapy*; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D005909:Glioblastoma / Q000628:therapy*; D006801:Humans; D016499:Radioimmunotherapy / Q000379:methods / Q000639:trends
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents